ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1058

Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study

Anna Moltó1, Adrien Etcheto1, Désirée van der Heijde2, Robert B. M. Landewé3, Filip van Den Bosch4, Maxime Dougados5 and on behalf of the ASAS-COMOSPA task force, 1Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, 2Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, 3Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands, Amsterdam, Netherlands, 4Univ Hosp, Ghent, Belgium, 5Université Paris René Descartes and Hôpital Cochin, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords:

Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects and CoMorbidities

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Increased risk of cardio-vascular disease, and osteoporosis is documented in SpA. Some of these comorbidities (e.g. cardiovascular disease risk) are subject to recommendations, with specific components relevant to rheumatic inflammatory diseases (e.g. yearly evaluation of BP, LDL-cholesterol). However, it is known that a gap exists between recommendations and their implementation in practice. The aim of this study was to evaluate: 1) the prevalence of SpA co-morbidities and risk factors for these comorbidities in different countries worldwide, 2) the gap between available recommendations and daily practice concerning prevention/management of these co-morbidities and 3) the number of risk factors detected due to the present initiative

Methods: International, cross-sectional study of consecutive SpA patients in routine care. Data comprise SpA characteristics, plus relevant cardiovascular, infection, cancer, osteoporosis and gastro-intestinal disorders.

Results:

Twenty-two participating countries (from 4 continents) included 3984 patients. Age: 44±14 years, disease duration 8±9 years, male gender: 65%, past or current axial (89%) and articular peripheral (56%) involvement; ASDASCRP: 2.0±1.1, BASFI 3.2±2.7, NSAID intake during last 3 months 68% and any past or current intake of methotrexate (33%), sulfasalazine (44%) or biologicals (44%). The most frequent diseases (past or current) found were osteoporosis (13%), gastro-duodenal ulcus (11%), cardiovascular events (myocardial infarction or stroke) (4%), solid cancers (3%), and hepatitis B infection (3%). The most frequent risk factors for these diseases were hypertension (34%), smoking (current or past (<3years)) 29%, dyslipidaemia (27%) and family history of cardiovascular disease and breast cancer (each 15%). Substantial inter-country variability was observed for the screening of co-morbidities (e.g. LDL-cholesterol measured at least in the last year from 8% (Taiwan) to 98% (Germany) or dentist visit in the last year from 0% (China) to 85% (Netherlands)). Evaluation of comorbidities and risk factors as part of this study unveiled previously undetected abnormalities [e.g. elevated blood pressure (14%), hyperglycemia (4%)] and emphasized the sub-optimal management of co-morbidities.

Conclusion:

This study suggests a) a high prevalence of co-morbidities in SpA, b) a substantial inter-country variability c) a highly variable detection of relevant risk factors. This study strongly suggests that rigorous application of systematic evaluation of co-morbidities may permit earlier detection, which ultimately may result in an improved outcome of patients with SpA.

Acknowledgements: This study was conducted under the umbrella of ASAS and thanks to an unrestricted grant from Abbvie, Pfizer and UCB.

Disclosure: A. Moltó, None; A. Etcheto, None; D. van der Heijde, AbbVie, 5,Amgen, 5,Astellas, 5,AstraZeneca, 5,Bristol-Myers Squibb, 5,Celgene, 5,Daiichi Pharmaceutical Corporation, 5,Eli Lilly and Company, 5,Galapagos, 5,Merck Pharmaceuticals, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,UCB Pharma, 5; R. B. M. Landewé, None; F. van Den Bosch, AbbVie, Celgene, Janssen, Novartis, Pfizer and UCB, 5,AbbVie, Celgene, Janssen, Novartis, Pfizer and UCB, 8; M. Dougados, None.

To cite this abstract in AMA style:

Moltó A, Etcheto A, van der Heijde D, Landewé RBM, van Den Bosch F, Dougados M. Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-comorbidities-in-spondyloarthritis-and-evaluation-of-their-monitoring-results-of-the-international-cross-sectional-asas-comospa-study/. Accessed .

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-comorbidities-in-spondyloarthritis-and-evaluation-of-their-monitoring-results-of-the-international-cross-sectional-asas-comospa-study/